ADILW (Adial Pharmaceuticals) Institutional Ownership: 0.00% (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADILW Adial Pharmaceuticals Inc ADILW
33 GF Score
Price $0.00
! 1 Warning Sign
View Full Analysis

What is Adial Pharmaceuticals Institutional Ownership?

Adial Pharmaceuticals ADILW 33 Institutional Ownership is 0.00% as of Sep. 09, 2026. GuruFocus rates ADILW with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adial Pharmaceuticals's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adial Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adial Pharmaceuticals's Float Percentage Of Total Shares Outstanding is N/A.

Adial Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Adial Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adial Pharmaceuticals Institutional Ownership Chart

Adial Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Institutional Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adial Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Institutional Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ADILW
33GF Score
Adial Pharmaceuticals Inc ADILW
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adial Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.00% mean?
Adial Pharmaceuticals (ADILW) has a Institutional Ownership of 0.00% as of Sep. 09, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Adial Pharmaceuticals and its competitors.
Is Adial Pharmaceuticals' Institutional Ownership too high?
Adial Pharmaceuticals' current Institutional Ownership is 0.00%. Overall, Adial Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Adial Pharmaceuticals' Institutional Ownership compare to CTXR and PBM?
Adial Pharmaceuticals' Institutional Ownership of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Adial Pharmaceuticals and its competitors. Adial Pharmaceuticals's current Institutional Ownership is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adial Pharmaceuticals stock overvalued right now?
Adial Pharmaceuticals (ADILW) has a current Institutional Ownership of 0.00%. The current Institutional Ownership is 0.00%. Adial Pharmaceuticals' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Adial Pharmaceuticals (ADILW), the current Institutional Ownership is 0.00% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adial Pharmaceuticals Business Description

Other Exchanges ADIL:USA
Address 4870 Sadler Road, Suite 300, Glen Allen, VA, USA, 23060
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
33GF Score

Get the complete analysis for ADILW

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price